Inspection readiness, from the regulator’s side of the table.

For eight years I was the FDA investigator walking into plants like yours: small molecules, biologics and combination products, in the United States and abroad. I know what gets looked at first, what makes an inspection run long, and what ends up on a 483. Now I help you find it and fix it before anyone from the agency does.

8
Years at FDA as investigator and health scientist
12+
Years in pharma, biotech and medical device quality
20+
Regulatory inspections directed with zero critical observations

What I do

Three ways I tend to be useful

How it works

Inspection readiness

Pre-approval, pre-license, for-cause and surveillance. I prepare sites the way an investigator would assess them, because that is the job I used to do.

  • Mock PAI, PLI and for-cause inspections
  • SME coaching and storyboard development
  • Facility and document-room readiness review

Quality systems & remediation

Building a quality system that scales, or repairing one that has already attracted attention.

  • QMS design, harmonisation and gap assessment
  • 483 and warning-letter response strategy
  • Data integrity programmes and controls

CDMO & supplier oversight

Knowing what your contract manufacturer is actually doing, and being able to show that you knew.

  • Risk-based supplier qualification programmes
  • CDMO audits and deficiency registers
  • Site-to-scope responsibility mapping

Is your site ready for the inspection you are not expecting?

Most of the findings I see were visible months earlier to anyone looking the way an investigator looks. A short conversation is usually enough to tell whether I can help.